A Phase 2 interventional study of LUM001 and Placebo in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 3 that started in 2014, is one of 6 in phase 2, and was the 3rd registered.
31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.
Browse Alagille Syndrome studies →2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Belgium, France, Germany and 5 more countries
Ages 2 mo+
Mirum Pharmaceuticals, Inc. · Sites in United States
By country, each count listing its studies:
Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2014.
This study's enrollment of 37 is above the median of 31 across 15 interventional studies indexed under Alagille Syndrome.
Median enrollment 31 across the 7 interventional studies, 47 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LUM001 for oral administration
Drug: LUM001
Placebo administered orally once each day
Drug: Placebo
LUM001 administered orally
Placebo administered orally
Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus
Pruritus was assessed using Itch report outcome measure (ItchRO\[Obs\]), administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). ItchRO(Obs) score ranged from 0 to 4, with the higher score indicating increasing itch severity. The highest score between the morning and evening ItchRO(Obs) reports represented the daily score: a measure of the worst itching over the previous 24-hour period.
Time frame: Baseline, Week 13/Early Termination
Change From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level
Fasting sBA level was measured by using a liquid chromatography mass spectrometry method.
Time frame: Baseline, Week 13/Early Termination
Change From Baseline to Endpoint (Week 13/Early Termination) in Liver Enzyme Levels
Liver enzyme levels of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase were reported here.
Time frame: Baseline, Week 13/Early Termination
Change From Baseline to Endpoint (Week 13/Early Termination) in Total and Direct Bilirubin Concentrations
Liver enzyme levels of total bilirubin and direct bilirubin were reported here.
Time frame: Baseline, Week 13/Early Termination
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An AE was any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.TEAEs were defined as AEs/SAEs that started or worsened after the study drug treatment.
Time frame: From the start of study drug administration up to Week 17
Study was conducted at 13 study centers in the United States and Canada, between 24 November 2014 (first participant first visit) and 16 November 2016 (last participant last visit).
| Milestone | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|
| Started | 8 | 11 | 6 | 12 |
| Completed | 7 | 11 | 6 | 11 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
Pruritus was assessed using Itch report outcome measure (ItchRO\[Obs\]), administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). ItchRO(Obs) score ranged from 0 to 4, with the higher score indicating increasing itch severity. The highest score between the morning and evening ItchRO(Obs) reports represented the daily score: a measure of the worst itching over the previous 24-hour period.
| Score on a scale | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus | -1.470 ± 0.3034 | -1.486 ± 0.2597 | -0.620 ± 0.3575 | -0.580 ± 0.2453 |
Fasting sBA level was measured by using a liquid chromatography mass spectrometry method.
| Micro moles per liter (mcmol/L) | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|
| Change From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level | -117.401 ± 46.2353 | -40.358 ± 34.8650 | -27.437 ± 46.2823 | -10.442 ± 32.6776 |
Liver enzyme levels of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase were reported here.
| Unit per liter (U/L) | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|
| Alanine Aminotransferase | 14.616 ± 17.9442 | 13.236 ± 14.9424 | 29.539 ± 19.6083 | -11.928 ± 13.9736 |
| Alkaline Phosphatase | 46.276 ± 38.9056 | -9.570 ± 30.8065 | -3.280 ± 42.1582 | 32.502 ± 29.9885 |
| Aspartate Aminotransferase | 20.241 ± 16.8467 | 11.851 ± 13.9367 | 16.539 ± 18.3472 | -3.691 ± 13.0114 |
| Gamma Glutamyl Transferase | -48.124 ± 46.2867 | 48.053 ± 36.1507 | -10.937 ± 48.8614 | -37.757 ± 34.7766 |
Liver enzyme levels of total bilirubin and direct bilirubin were reported here.
| Milligrams per deciliter (mg/dL) | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|
| Total Bilirubin | -0.291 ± 0.3777 | -0.353 ± 0.3014 | -0.804 ± 0.4021 | 0.104 ± 0.2847 |
| Direct Bilirubin | -0.333 ± 0.2086 | -0.305 ± 0.1672 | -0.508 ± 0.2243 | 0.011 ± 0.1591 |
An AE was any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.TEAEs were defined as AEs/SAEs that started or worsened after the study drug treatment.
| Participants | Maralixibat 14 mcg/kg/Day | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|---|
| TEAE | 1 | 7 | 9 | 5 | 12 |
| Serious TEAE | 0 | 1 | 0 | 0 | 0 |
Collected over From the start of study drug administration up to Week 17. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maralixibat 14 mcg/kg/Day | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Maralixibat 70 mcg/kg/Day | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Maralixibat 140 mcg/kg/Day | 0/11 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| Maralixibat 280 mcg/kg/Day | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Placebo | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | Maralixibat 14 mcg/kg/Day | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/1 | 1/7 | 0/11 | 0/6 | 0/12 |
| Event | Maralixibat 14 mcg/kg/Day | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo |
|---|---|---|---|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/1 | 0/7 | 0/11 | 0/6 | 2/12 |
| Alanine aminotransferase increasedInvestigations | 1/1 | 1/7 | 0/11 | 0/6 | 0/12 |
| Aspartate aminotransferase increasedInvestigations | 1/1 | 0/7 | 0/11 | 0/6 | 0/12 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/1 | 0/7 | 0/11 | 0/6 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 0/7 | 6/11 | 2/6 | 6/12 |
| PyrexiaGeneral disorders | 0/1 | 2/7 | 2/11 | 2/6 | 3/12 |
| NasopharyngitisInfections and infestations | 0/1 | 1/7 | 0/11 | 2/6 | 0/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/1 | 2/7 | 2/11 | 2/6 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/1 | 2/7 | 1/11 | 1/6 | 2/12 |
| HeadacheNervous system disorders | 0/1 | 2/7 | 0/11 | 1/6 | 0/12 |
The Safety Population included all participants who were randomly assigned to study treatment and received at least one dose of the study drug.
| Age, Continuous(Years) | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.4 ± 4.75 | 8.6 ± 4.32 | 5.5 ± 4.76 | 5.5 ± 4.19 | 6.8 ± 4.48 |
| Sex: Female, Male(Participants) | Maralixibat 70 mcg/kg/Day | Maralixibat 140 mcg/kg/Day | Maralixibat 280 mcg/kg/Day | Placebo | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 4 | 6 | 16 |
| Male | 6 | 7 | 2 | 6 | 21 |
Ran from Nov 2014 to primary completion in Nov 2016, 23 months.
Results were first posted in Jan 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat